Plain-English translation of NCT07243782 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety and effectiveness study of Cosentyx, a medication already approved to treat certain types of arthritis and skin disease. The study will follow patients in Korea who are receiving this medication as part of their normal medical care, tracking how well it works and whether any side effects occur. Researchers will collect information from routine doctor visits—no extra tests or procedures will be required.
Regulatory agencies sometimes require long-term follow-up studies to make sure approved medications continue to be safe and effective when used by many different patients in real-world settings. This study helps ensure the medication is working well for people with these specific conditions in Korea.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will simply continue receiving the medication and regular doctor's care as you normally would. Your doctor will collect information about how the medication is working and any side effects during your routine appointments. No extra hospital visits, procedures, or tests beyond your regular care will be needed—the study is designed to fit into your normal medical schedule.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
South Korea
Sponsor
Novartis Pharmaceuticals
Enrollment target
~76 participants
Started
December 2025
Primary completion
June 2027
Age range
6 Years – 100 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.